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ABSTRACT
Purpose. Cancer patients carry rising burdens of health care-
related out-of-pocket expenses, and a growing number of pa-
tients are considered “underinsured.” Our objective was to
describe experiences of insured cancer patients requesting
copayment assistance and to describe the impact of health
care expenses onwell-being and treatment.
Methods.We conducted baseline and follow-up surveys re-
garding the impact of health care costs on well-being and
treatment among cancer patients who contacted a national
copayment assistance foundation along with a comparison
sample of patients treated at an academicmedical center.
Results.Among 254 participants, 75%applied for drug copay-
ment assistance. Forty-twopercent of participants reported a
significant or catastrophic subjective financial burden; 68%
cut back on leisure activities, 46% reduced spending on food
and clothing, and 46% used savings to defray out-of-pocket
expenses. To save money, 20% took less than the prescribed
amount of medication, 19% partially filled prescriptions, and
24% avoided filling prescriptions altogether. Copayment as-
sistance applicants were more likely than nonapplicants to
employat leastoneof these strategies todefray costs (98%vs.
78%). In an adjusted analysis, younger age, larger household
size, applying for copayment assistance, and communicating
with physicians about costswere associatedwith greater sub-
jective financial burden.
Conclusion. Insured patients undergoing cancer treatment
and seeking copayment assistance experience considerable
subjective financial burden, and they may alter their care to
defray out-of-pocket expenses. Health insurance does not
eliminate financial distress or healthdisparities among cancer
patients. Future research should investigate coverage thresh-
olds that minimize adverse financial outcomes and identify
cancerpatientsat greatest risk for financial toxicity.TheOncol-
ogist2013;18:381–390
Implications for Practice: The number of insured patients is increasing, but insured patients are paying more out of pocket for
cancercaredueto increasedcost sharing.Asa result, thenumberofunderinsuredcancerpatients is increasing.Patientsare faced
with greater out-of-pocket health care costs, but treatment decision making is often made without consideration of these ex-
penses. Inour study, insuredpatientsundergoingcancer treatmentandseekingcopaymentassistanceexperiencedconsiderable
subjective financialburden,andtheyalteredcaretodefrayout-of-pocketexpenses.Health insurancedoesnoteliminate financial
distress or health disparities among cancer patients. Financial distress or “financial toxicity” as a result of disease or treatment
decisionsmight be considered analogous to physical toxicity andmight be considered a relevant variable in guiding cancerman-
agement.Understandinghowandamongwhomtobestmeasure financial distress is critical to thedesignof future interventional
studies.
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LearningObjectives Describe the experiences of insured cancer patients requesting copayment assistance in order
to better understand the challenges of underinsurance.
Describe the impact of costs on thewell being of insured cancer patients.
Evaluate the impact of costs on the treatment received by insured cancer patients.
TheOncologist®
Economics of Oncology Practice
CM
E
TheOncologist2013;18:381–390 www.TheOncologist.com ©AlphaMed Press 2013
INTRODUCTION
Cancer treatment has made remarkable strides, yielding im-
provements in patient outcomes, but those improvements
have come at increasing costs [1]. As health care costs in-
crease, insurers have shifted some of the cost burden to pa-
tients through higher deductibles, rising copayments, and
coinsurance, resulting in higher out-of-pocket expenses [2].
These out-of-pocket–related expenses are higher among pa-
tients with cancer than among patients with other conditions
[3, 4]. As a result of growing expenses, even patients with in-
surancemay require financial assistance from government or
nonprofit national copayment assistance organizations to
guarantee access to therapy and tomitigate the financial bur-
denof cancer care [5]. Though thenumberof insuredpatients
is estimated to increase in the era of the Affordable Care Act,
rising out-of-pocket costs dispute the adequacy of insurance
for providing affordable cancer care [6, 7]. Patients who carry
insurancebut still pay a significant portionof health care costs
out of pocket are considered underinsured [1].
In thecontextof increasinghealth care costs,wesought to
betterunderstandthedegreeof financialhardshipandthe im-
pact of cancer costs on thewell-being of underinsured cancer
patients. Out-of-pocket expenses are one measure of under-
insurance, particularly when those expenses impact patient
well-being, treatment choices, or outcomes [8, 9]. We can
viewtheadverse impactsofout-of-pockethealthcarecostsas
a formof treatment-related toxicity, or “financial toxicity.” As
withphysical toxicity resulting fromcancer treatment, certain
patients might be predisposed to greater financial toxicity
than others. Though prior work has investigated the burden
of out-of-pocket expenses among cancer patients, we
sought to specifically evaluate the prevalence and impact
of financial toxicity among ahigh-risk groupof patientswho
had applied for copayment assistance to better understand
the challenges posed by underinsurance. Hence, we con-
ducted an exploratory pilot study to evaluate the degree of
objective financial burden and subjective financial burden
among insured cancer patients seeking copayment assis-
tance through anational nonprofit foundation and among a




Eligible participants were patients with solid tumors actively
receiving chemotherapy or hormonal therapy. Participants
were recruited fromtwosources: theHealthWell Foundation,
a 501(c)(3) nonprofit organization that assists patients with
prescription drug copayments, coinsurance, and premium
payments, andDukeUniversityMedicalCenter. Patientswere
referred to HealthWell by their health care providers, other
copayment assistance foundations, reimbursement hotlines,
pharmacies, or social workers [10]. Between June 2010 and
May2011, HealthWell staff askedpatientswho contacted the
Foundation for financial assistance if they were interested in
participating in cost-related research. Potential participants
were informed that receipt of financial assistance from
HealthWell would be independent of their decision to partici-
pate in research. For those who agreed, HealthWell for-
warded contact information to investigators at Duke, who
then contacted patients for eligibility screening. A conve-
nience sample of adult patients receiving chemotherapy or
endocrine therapy for solid tumorsatDukeUniversityMedical
Center were recruited by physician referral during routine
clinic visits; the primary intent of enrolling these patients was
to provisionally compare the subjective financial experience
and objective financial burden among a cohort of patients
seeking copayment assistance with those of an unselected
sampleofpatientsat anacademic cancer center.Aminorityof
patients recruited at Duke reported seeking copayment assis-
tance and theywere analyzed as part of the copayment assis-
tance cohort. We conducted a sensitivity analysis comparing
HealthWell participants with Duke participants (regardless of
copayment application status) and found no notable differ-
ences in results.
Study Design
This was an exploratory, observational study of self-re-
ported, treatment-related costs (objective financial bur-
den) and patient-reported subjective financial burden
among patientswith cancer seeking copayment assistance.
All participants completed a baseline survey at the time of
enrollment assessing sociodemographics and strategies
used to cope with out-of-pocket expenses. Questions per-
taining to cost-coping strategies were based on a study by
Schrag et al. [11].
Beginning 1month after the baseline survey, participants
completed monthly cost diaries for up to 4 months. Initially,
the study included fourweekly cost diaries for the firstmonth,
followedby threemonthly diaries. As a result of lowparticipa-
tion in the weekly diary component and perceived burden on
participants,weamendedthestudydesign to fourmonthlydi-
aries. Patients were asked to estimate their monthly cancer-
related out-of-pocket expenses (objective financial burden),
including prescription and nonprescriptionmedications, doc-
tor visit copayments, insurance premiums, travel, special di-
ets, alternative therapies, devices and equipment, time off
work, and other services, such as child care. Insurance premi-
ums were included in the calculation of out-of-pocket ex-
penses, consistent with a landmark survey on health care
expenses and underinsurance [1].
The baseline survey and cost diary items were developed
and piloted in focus groups of patients undergoing cancer
treatment at Duke. All surveys were completed either online
oronpaper, basedonparticipantpreference.DukeUniversity
Health System’s Institutional Review Board approved this
study.
Statistical Analyses
Descriptive statistics summarized sociodemographics, dis-
ease and treatment characteristics, out-of-pocket expenses,
and cost-coping strategies. Costs related to travel were esti-
mated bymultiplyingmiles traveled for cancer care by $0.51,
the 2011mileage reimbursement rate set by the Internal Rev-
enue Service. We used the following equation to determine
indirect costs resulting from lost wages: [(hours worked if
healthy) (hours actuallyworked)] federalminimumwage
of $7.25.




We estimated the proportion of underinsured partici-
pants by first converting annual income to a monthly income
range (e.g., $40,000–$59,999/year was converted to $3333–
$4999/month). For patients who reported income in either
the “less than $20,000/year” or “greater than $60,000/year”
categories, we assumed $20,000 or $60,000, respectively, as
their annual income. We then divided the median out-of-
pocket expenses reportedbyeachparticipant byhigh and low
values of their monthly income range. Similar methods have
beenusedpreviously to report proportionof income spent on
health care [12]. We calculated the proportion of underin-
sured patients, with underinsurance defined as insured pa-
tients who spend at least 10% of their annual household
income out of pocket on health care [1].
2 tests were used to assess differences between pa-
tients who applied for copayment assistance and those
who did not. Logistic regression was used to assess the re-
lationship between sociodemographics and subjective fi-
nancial burden. Variables were selected for inclusion in
multivariate models using a combination of the statistical
selection criterion of p  .25 in unadjusted analyses and
clinical relevance. A p value  .05 in the final model was
considered statistically significant. Pearson correlations
were calculated to determine the degree of correlation be-




Between July2010and July2011, among677eligiblepatients,
258 agreed to participate and completed baseline surveys,
representing a response rate of 38% (Fig. 1). Nonresponders
included those who declined to participate and those who
agreedbutdidnotcompleteabaselinesurvey.Fouruninsured
participants were excluded from this analysis, which focused
on insured participants, thereby resulting in an effective sam-
ple size of 254. Participantswere enrolled nationwide (Fig. 2),
with175 (68%) recruitedviaHealthWell andtheremainder re-
cruitedatDuke.Themeanandmedianagewas64years (Table
1). Eightypercentwerewhite,86%werewomen,and71%had
breast cancer. Overall, 81% carried prescription drug cover-
age. Fifty-eight percent reported discussing costs with their
doctor.
One hundred ninety (75%) participants applied for pre-
scription drug copayment assistance. Among copay appli-
cants, 174 (92%) were enrolled via HealthWell. As
described in Table 1, participants who applied for copay-
ment assistance differed in many regards from those who
did not apply.
Out-of-Pocket Expenses
Sixty-three percent of participants completed a baseline sur-
vey and at least one cost diary, 32% completed two diaries,
20% completed three diaries, and 13% of patients completed
abaseline survey andall four cost diaries. Cost calculations fo-
cused on the 159 (63%) participants who completed at least
one cost diary. Excluding indirect costs, participants spent a
median of $456/month (interquartile range, $213–$827) out
of pocket on cancer care-related expenses. Table 2 lists the
median amount spent per category of expense. The median
proportion of income spent out of pocket did not differ signif-
icantly between copayment applicants (17%; range, 8%–35%)
and nonapplicants (15%; range, 6%–28%; p .31).
Per an accepted definition of underinsurance (insured pa-
tients who spend greater than 10% of their annual household
income out of pocket on health care [1]), 55% of those com-
pletingcostdiarieswereunderinsured, comparedwith22%of
all U.S. adults [1]. In a sensitivity analysis using amore conser-
vative20%-of-incomethreshold, 35%ofparticipantswereun-
derinsured, compared with 13% of U.S. adults, using this
higher threshold [3]. However, copayment assistance appli-
cantsweremore likely thannonapplicants tobeunderinsured
using the 10% threshold (59% vs. 39% underinsured; p 
.042), but not using the 20% threshold (38% vs. 26% underin-
sured; p .055).
Participants reported their subjective financial burden re-
sulting from cancer-related out-of-pocket expenses (Table 3).
Among the 250 participants who responded to this item, 42%
reported a significant or catastrophic burden. 2 analysis re-
vealed that, compared with nonapplicants, copayment assis-
tance applicants were more likely to report a higher financial
burden (Table 3) (p  .004). Figure 3 presents a multivariate
analysis assessing the characteristics associatedwith ahigh fi-
nancial burden. In an adjusted analysis, older age and a
smallerhouseholdsizewereassociatedwith less financialbur-
den. Applying for copayment assistance and communicating
with physicians about the cost of care were associated with
greater subjective financial burden.
Subjective Financial Burden andWell-Being
Participantsaltered their lifestyles toaffordprescriptionmed-
ications and cancer care in general (Table 4). Overall, 68% cut
backon leisure activities, 46% reduced spendingonbasics like
food and clothing, 46% used their savings, and 17% sold pos-
sessions or property, all to help defray cancer care-related
out-of-pocket expenses. Copayment assistance applicants
were more likely than nonapplicants to employ at least one
strategy to cope with costs (98% vs. 78%; p  .001). Among
those who employed at least one strategy, copayment assis-
tance applicants were more likely to reduce spending on lei-
sure activities (p .005), reduce spending on food or clothing
(p .021), and borrowmoney or use credit (p .001).
Using cost-coping strategies to help pay for cancer care
was positively correlated with reporting a high subjective fi-
nancial burden (r  0.49; p  .01). We further examined this
correlation by focusing on each individual coping strategy
(supplemental online Table 1). All strategies except “Worked
more hours to help pay for your cancer care”were associated
with high subjective financial burden.
Subjective Financial Burden andQuality of Care
As one of many strategies used to alleviate the financial bur-
denof cancer care, participants reportednoncompliancewith
care (Table 4). Overall, 20% took less than the prescribed
amount of medication, 19% filled only part of a prescription,
and 24% avoided filling prescriptions at all. A smaller portion
of patients avoided procedures (7%) or tests (9%) because of
costs. Seven percent spread out chemotherapy or clinic ap-
pointments, and 4% skipped appointments to savemoney.
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This study provides a timely window into the financial impact
of cancer care,with aparticular focuson insuredpatientswho
applied for copaymentassistance. In this select cohortofhigh-
risk patients, participants experienced high subjective finan-
cial burden and altered their lifestyles and care to defray out-
of-pocket expenses.
These data provide one of the first evaluations of the neg-
ative personal financial impact of cancer care among the un-
derinsured—a conceptwe call “financial toxicity.” Thoughwe
found substantial potential for financial toxicity among pa-
tients with cancer, it was not seen exclusively among those
who sought copayment assistance. The broader range of pa-
tients at risk for subjective financial burden suggests aneed to
better assess cancer-related financial hardship and to expand
educational interventions targeted to both clinicians and
patients.
Who Is at Risk for Financial Burden?
Recent studies have detailed the burden of health care-re-
lated out-of-pocket expenses [3, 4, 8, 9, 12–14]. Our study is
among the first to evaluate the subjective financial burden
and cost-related experiences of insured cancer patients who
applied for copayment assistance. Consistentwith recent evi-
dence, we found that younger patients and those with larger
householdswereat greater risk for financial burden.Aswould
be expected, applying for copayment assistance was also as-
Figure 1. Derivation of cohorts. (A):Derivation of HealthWell study cohort. (B):Derivation of Duke study cohort. Although ineligibility
reasonwas not recorded, the only eligibility criterionwas actively receiving hormonal therapy or chemotherapy.




sociated with greater subjective financial burden. However,
themedian proportion of income spent out of pocket did not
differ significantlybetweencopaymentapplicantsandnonap-
plicants.This suggests thatmeasuringout-of-pocketexpenses
as a proportion of income might not be sufficient to capture
objective financial burden, and some subjective assessment
should also be considered to identify patientswhomay bene-
fit from intervention.
HowDo Expenses Impact PatientWell-Being?
Participants struggling to pay for their cancer treatment al-
tered their lifestyles considerably to defray out-of-pocket ex-
penses. Our results are consistent with the limited literature
addressing how out-of-pocket expenses impact cancer pa-
tients’ lives [9, 15]. We found that copayment assistance ap-
plicants were more likely than nonapplicants to employ at
least one lifestyle-altering strategy to cope with costs. How-
ever, thedirectionof theassociation isunclear, andwedidnot
directlyassess the reason for seekingcopaymentassistanceat
the time of application. Given that copayment assistance is a
poorly understood support mechanism, further work is
needed to assess the triggers for requesting assistance and
the outcomes associated with receiving (or not receiving) as-
sistance.
The similarities and differences among participants in
terms ofwhich cost-saving strategieswere employed provide
meaningful insights into how patients alter their behavior
when confronted with high out-of-pocket health care costs.
Both copayment applicants and nonapplicants were equally
likely tosellpossessions,work longerhours,have familymem-
berswork longerhours, anduse their savings; thesebehaviors
are particularly meaningful because the median age for all
participants approached retirement age. However, copay-
ment assistance applicants were more likely than nonappli-
cants to reduce spending on food, clothing, and leisure
activities tohelppay for care. This patternof coping strategies
suggests that, as financial burden increases, patients work
more and exhaust savings before cutting back on daily ex-
penses. Furthermore, all cost-coping strategies except
“Worked more hours to help pay for your cancer care” were
associated with high subjective financial burden. This explor-
atoryanalysis suggests that, forsomepatients, cuttingbackon
leisure activities to pay for cancer caremight be as distressing
as spending savings. Future research should address how pa-
tients prioritize lifestyle changes and alter financial behaviors
in the face of significant out-of-pocket expenses.
HowDo Expenses Impact Cancer Treatment?
Participants reported taking lessmedication than prescribed,
replacing prescription medications with over-the-counter
drugs, and taking medications prescribed for others in order
to defray costs. A minority of participants reported skipping
appointments or declining procedures because of costs.
These findings confirm a disturbing link between costs and
medication compliance [9, 16]. Our results suggest that the
risk for noncompliance is not isolated to patients applying for
drug copayment assistance. To the extent that cost sharing is
intended to boost patient-directed decision making in health
care and increase the value of health care, these findings sug-
gest a potential for unintended adverse consequences that
may result in higher downstreamhealth care costs [17].
Our data suggest that the costs of care are insufficiently
addressed in discussions between patients and physicians;
over one quarter of copayment applicants did not discuss
costswith their doctor.Our sample is saturatedwith thoseap-
plying for financial assistance, which in turn was associated
Figure 2. Participants by state.
385Zafar, Peppercorn, Schrag et al.
www.TheOncologist.com ©AlphaMed Press 2013
CM
E








assistancea (n 190) p value
Mean age, yrs 64 (range, 29–88) 58 (range, 34–81) 66 (range, 29–88) .001
Female gender 219 (86%) 41 (64%) 178 (94%) .001
Race
White 203 (80%) 50 (78%) 153 (81%) .738
Black 34 (13%) 19 (14%) 25 (13%)
Asian 2 (0.8%) 0 2 (1%)
Other/unknown 15 (6%) 5 (8%) 10 (5%)
Primary cancer site
Breast 181 (71%) 25 (39%) 156 (82%) .001
Colorectum 23 (9%) 15 (23%) 8 (4%)
Lung 7 (3%) 4 (6%) 3 (2%)
Other solid tumors 43 (17%) 20 (31%) 23 (12%)
Married 138 (54%) 47 (73%) 91 (48%) .001
Annual household income
$40,000 159 (63%) 16 (25%) 143 (75%) .001
$40,000 57 (22%) 31 (48%) 26 (14%)
Prefer not to say/unknown 38 (15%) 17 (27%) 21 (11%)
Employment status
Employed full time 40 (16%) 19 (30%) 21 (11%) .001
Employed part time 20 (8%) 4 (6%) 16 (8%)
Notworking outside the home 40 (16%) 10 (16%) 30 (16%)
Retired 138 (54%) 25 (39%) 113 (59%)
Self-employed 5 (2%) 4 (6%) 1 (0.5%)
Unknown 11 (4%) 2 (3%) 9 (5%)
Level of education
High school or less 132 (52%) 23 (36%) 109 (57%) .007
Associates 9 (4%) 5 (8%) 4 (2%)
College 86 (34%) 25 (39%) 61 (32%)
Postgraduate 19 (7%) 9 (14%) 10 (5%)
Prefer not to say 8 (3%) 2 (3%) 6 (3%)
Insuranceb
Medicare 151 (59%) 22 (34%) 129 (68%) .001
Medicaid 10 (4%) 3 (5%) 7 (4%) 1
Employer-provided insurance 72 (28%) 38 (59%) 34 (18%) .001
Personally purchased insurance 43 (17%) 7 (11%) 36 (19%) .199
Veterans Administration 2 (0.8%) 1 (2%) 1 (0.5%) 1
Personally purchased supplemental 73 (29%) 7 (11%) 66 (35%) .001
Other 45 (18%) 10 (16%) 35 (18%) .751
Prescription drug coverage
Yes 206 (81%) 56 (88%) 150 (79%) .252
No 30 (12%) 6 (9%) 24 (13%)
Unknown 18 (7%) 2 (3%) 16 (8%)
Household size
1 76 (30%) 6 (9%) 70 (37%) .001
2 170 (67%) 53 (83%) 117 (62%)
Unknown 8 (3%) 5 (8%) 3 (2%)
Duration of chemotherapy
1mo 4 (2%) 3 (5%) 1 (0.5%) .001
1–6mos 45 (18%) 19 (30%) 26 (14%)
6–12mos 35 (14%) 11 (17%) 24 (13%)
12mos 170 (67%) 31 (48%) 139 (73%)
Major surgery in the last 2months
No 228 (90%) 51 (80%) 177 (93%) .004
Yes 25 (10%) 12 (19%) 13 (7%)
Unknown 1 (0.4%) 1 (2%) 0
Metastatic disease
No 142 (56%) 17 (27%) 125 (66%) .001
Yes 93 (37%) 44 (69%) 49 (26%)
Unknown 19 (7%) 3 (5%) 16 (8%)
Discussed costs with doctor
Yes 148 (58%) 9 (14%) 139 (73%) .001
No or unknown 106 (42%) 55 (86%) 51 (27%)
aThemajority of patients applying for copayment assistancewere recruited from the HealthWell Foundation (n 175); 15were recruited from
Duke.
bn values do not sum to 254 in this category becausemultiple responseswere possible.




withahigher likelihoodofdiscussingcostswithadoctor. In the
general population, in which the rates of financial assistance
application are lower, costsmight bediscussed at a lower rate
than those described in our study. Given the high levels of fi-
nancial burden identified in our study population, our data
might underestimate the number of patients who do not dis-
cuss the costs of cancer care in the clinic. Of note, we did not
ask participants if they wanted to discuss costs or if they
wanted costs to play a role in treatment decisionmaking. Re-
search suggests that oncologists feel that the costs of care are
important, but that they are poorly prepared to discuss costs
with patients in the clinic. Our findings—in conjunction with
calls fromtheAmericanSocietyofClinicalOncologytoaddress
the costs of cancer care in the clinic—suggest a need for fur-
ther efforts at clinician education in this area [18].
What little is known about patient preferences regarding
cost discussions is based on the general medicine literature
[19], but those findings might not apply to cancer treatment.
In treating hypertension, for example, patients aremore will-
ing to modify treatment based on costs because a broad cost
spectrumofdrugs isavailable totreathypertension.However,
for any given tumor type,abroadspectrumofanticancer thera-
pies is not necessarily available to patients and providers, so the
samewillingness to alter treatmentmight not apply [20, 21]. Fu-
ture studies should address patients’ willingness to include out-
of-pocket costs in treatment decision making and patients’
understandingof thepotential implicationsofdoing so.
Our findings are subject to limitations. There are several
sources of bias that may limit the generalizability of this study.
First, we recruited the majority of patients through the Health-
WellFoundation.Thispopulationisnotrepresentativeofalladult
patients with cancer, and as shown through comparison with
Dukeclinicpatients, itdoesnotrepresentallpatientswhoareun-
derinsured or facing financial hardship. However, this limited
sample does provide one of the first windows into the demo-
graphics and financial experiences of patients with cancer seek-
ing copayment assistance. Similarly, the Duke participants were
selected as a convenience sample to allow for comparison be-
tweenpatients applying toHealthWell and an unselected popu-
lation, but they are not representative of patients seeking
oncology care in the community setting, or even of all patients
seeking care at academic cancer centers. However, the fact that
financial hardship and underinsurance were prevalent even in
this selectpopulationsuggests that thefinancial challenges iden-
tifiedhereare likely tobewidespread.
In terms of the broader generalizability of our sample,
Dukestudyparticipantsweresimilar toallDukeCancerCenter
patients receiving treatment in terms of age, race, and insur-
ance type (Sarah Bacik, personal communication, 2012).
HealthWell participants were predominantly white women
with breast cancer. They had a mean age of 66 years. Health-
Well reports that the average age of applicants is 65 years,
and 67% of those applying for assistance are women [10]. As-
sistance is provided on the basis of specific diseases, not can-
cer in general. At the time of our study, HealthWell had funds
to support patients with breast, colorectal, and lung cancer
butnotprostate cancer; thismayhavecontributed to thegen-
der and disease imbalance in our sample.
Table 2. Medianmonthly OOP expenses by category
Expense category
Full cohort completing cost
diary,median (IQR)
(n 159)





(n 128) p value
Lost wages $0 ($0–$217.5) $290 ($0–$522) $0 ($0–$51) .001
Insurance premium $120 ($13.5–$285) $74.5 ($0–$208) $122 ($48–$286) .26
Prescriptionmedication $56 ($11–$132.5) $50 ($2.5–$120) $65 ($13–$143) .42
Other $0 ($0–$24) $0 ($0–$17.5) $0 ($0–$29.5) .58
Doctor visit copayments $0 ($0–$50) $25 ($0–$100) $0 ($0–$40) .039
Equipment $0 ($0–$18) $0 ($0–$60) $0 ($0–$7) .018
Diet $0 ($0–$32) $15 ($0–$160) $0 ($0–$15) .006
Travel $28 ($2–$111) $177.5 ($68–$314) $20 ($0.5–$62) .001
Alternative therapies $0 ($0–$0) $0 ($0–$0) $0 ($0–$0) .82
Nonprescriptionmedication $15 ($0–$30) $19 ($2.5–$30) $14 ($0–$30) .46
Total direct OOP costs $456 ($213–$827) $708 ($330–$1,300) $432 ($196–$724) .019
Abbreviations: IQR, interquartile range; OOP, out of pocket.
Table 3. Subjective financial burden resulting from cancer-related out-of-pocket expenses
Degree of financial burden
Full cohort
(n 246)a
Did not request copayment
assistance (n 62)
Requested copayment
assistance (n 128) p value
Not a financial burden at all 16 (7%) 9 (15%) 7 (4%) .004
Minor financial burden 37 (15%) 13 (21%) 24 (13%) .004
Moderate financial burden 90 (37%) 23 (37%) 67 (36%) .004
Significant financial burden 80 (33%) 15 (24%) 65 (35%) .004
Catastrophic financial burden 23 (9%) 2 (3%) 21 (11%) .004
an 8missing responses.
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In addition, the baseline survey response rate was 38%,
which introduces the possibility of nonresponse bias. How-
ever, this exploratory study on personal finances focused on
elderly cancer patients facing financial hardship. Surveying
low-income or financially distressed populations is challeng-
ing, as evidenced by the low response rates of other survey
studies focused on these populations [9, 22, 23].
Our sample was enriched with underinsured patients,
though one in five adults in the U.S. is underinsured [1].
Although not all patients in our sample met some of the con-
ventional definitions of underinsurance, these data are
among the first to evaluate how insured cancer patientsman-
age financial burdens. Not all patients completed a cost diary:
63%of respondentscompletedat leastonemonthlycostdiary
and only 13% completed all four. Those who did not were
more likely to be older, have Medicare, and have received fi-
nancial assistance. This suggests that our measured out-of-
pocket expenses are possibly underestimated. Our subjective
measure of financial burdenwas not validated. It was piloted,
and high financial burdenwas correlatedwith the use of cost-
saving strategies. Finally, reported costs might have included
those incurred from health care unrelated to cancer, but par-
ticipants were directed to limit their cost reporting to cancer
care-related costs. This study focused on costs related to can-
cercare,butcopaymentassistance foundationsprovide funds
for treatment of other chronic illnesses [10]. Future research
should investigatewhetherornot theconceptof financial tox-
icity also applies to the treatment of other chronic diseases.
CONCLUSION
Insured patients undergoing cancer treatment and seeking
copayment assistance experience a considerable subjec-
tive financial burden. They may exhaust their savings, take
on excessive debt, and face choices between health care
and other basic necessities to savemoney. Insured patients
who did not apply for copayment assistance also faced fi-
nancial hardship, suggesting that those applying for finan-
cial assistance represent the tip of the iceberg of patients
with financial difficulties. Financial distress or “financial
toxicity” as a result of disease or treatment decisionsmight
be considered analogous to physical toxicity and might be
considered a relevant variable in guiding cancer manage-
ment. Understanding how and among whom to best mea-
sure financial distress is critical to the design of future
interventional studies. This pilot study is the first to assess
financial distress among insured patients applying for co-
pay assistance. Our data suggest that copayment assis-
tance applicants are enriched for, but not the exclusive
bearers of, financial distress. These data also confirm the
feasibility of measuring financial distress among copay-
ment assistance applicants, with potential relevance to
fields outside oncology. These data will support the design
Figure3. Characteristics associatedwithgreater financial burden inanadjustedmultivariateanalysis (n195).Variables considered in
the univariate analysis included gender, application for copayment assistance, presence ofmetastatic disease, education, age, income
(excluded from themultivariate analysis because of 15%missing), race, marital status, employment, household size, recent major sur-
gery, communication with doctor about costs, insurance type, out-of-pocket payments for health insurance, presence of prescription
drug coverage, and duration of chemotherapy.
Abbreviations: CI, confidence interval; OR, odds ratio.




of a study assessing the differential impact of financial dis-
tress on treatment-relateddecisionmaking throughout the
continuum of cancer care.
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(n 190) p valuea
Strategies to copewith cost of prescriptionmedications
Altered thewaymedicationwas obtained
Obtained samples fromdoctor 139 (55%) 19 (30%) 120 (63%) .001
Shopped around at pharmacies for the lowest price 119 (47%) 17 (27%) 102 (54%) .001
Asked doctor for less expensivemedication 121 (48%) 18 (28%) 103 (54%) .001
Purchased over-the-countermedications to replace prescriptions 38 (15%) 9 (14%) 29 (15%) .976
Purchasedmedication in another country 13 (5%) 3 (5%) 10 (5%) 1
Usedmedications prescribed for another person 10 (4%) 3 (5%) 7 (4%) 1
Obtainedmedications through Veterans Affairs 4 (2%) 0 4 (2%) NA
Altered lifestyle
Reduced spending on basics like food and clothing 118 (46%) 17 (27%) 101 (53%) .001
Borrowedmoney or used credit to pay formedications 107 (42%) 13 (20%) 94 (49%) .001
Stayed inpatient an extra day to getmedication coverage 6 (2%) 2 (3%) 4 (2%) 1
Alteredmedication use
Did not fill the prescription 62 (24%) 11 (17%) 51 (27%) .166
Filled only part of the prescription 52 (20%) 7 (11%) 45 (24%) .029
Took less than prescribed amount 48 (19%) 7 (11%) 41 (22%) .060
Strategies to copewith cancer care expenses
Altered care
Spread out clinic or chemotherapy appointments 19 (7%) 3 (5%) 16 (8%) .479
Not had a recommended test (like a computed tomography scan) 23 (9%) 5 (8%) 18 (9%) .882
Chosen one doctor over another 17 (7%) 1 (2%) 16 (8%) .107
Not had a recommended procedure 17 (7%) 3 (5%) 14 (7%) .651
Missed clinic or chemotherapy appointments 11 (4%) 2 (3%) 9 (5%) .847
Altered lifestyle
Reduced spending on leisure activities like vacations, eating out, ormovies 173 (68%) 34 (53%) 139 (73%) .005
Used all or a portion of savings to pay for cancer care 117 (46%) 28 (44%) 89 (47%) .776
Reduced spending on basics like food or clothing 117 (46%) 21 (33%) 96 (51%) .021
Borrowedmoney or used credit 90 (35%) 11 (17%) 79 (42%) .001
Sold possessions or property 42 (17%) 10 (16%) 32 (17%) .974
Workedmore hours 30 (12%) 3 (5%) 27 (14%) .069
Had familymembersworkmore hours 37 (15%) 10 (16%) 27 (14%) .942
Percentages do not sum to 100 becausemultiple responseswere possible.
aUnadjusted p value is calculated based on two-sample proportion test.
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